Real-life effects of benralizumab on airway oscillometry in severe eosinophilic asthma
Introduction Eosinophil depletion with benralizumab reduces exacerbations and improves disease control and FEV1 in patients with severe eosinophilic asthma. However, few studies have investigated the effect of biologics on small airways dysfunction (SAD) even though the latter correlates better with...
Main Authors: | Brian J Lipworth, Rory Chan |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-12-01
|
Series: | BMJ Open Respiratory Research |
Online Access: | https://bmjopenrespres.bmj.com/content/10/1/e001472.full |
Similar Items
-
Medium-term repeatability for airwave oscillometry in patients with severe asthma taking benralizumab
by: Rory Chan, MBChB, PhD, et al.
Published: (2023-08-01) -
Patient-Reported Outcomes with Benralizumab in Patients with Severe Eosinophilic Asthma and Severe Chronic Rhinosinusitis with Nasal Polyps
by: Rory Chan, et al.
Published: (2023-03-01) -
Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience
by: Giulia Scioscia, et al.
Published: (2023-06-01) -
Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma
by: Gómez-Bastero Fernández A, et al.
Published: (2022-05-01) -
Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study
by: Takanori Numata, et al.
Published: (2020-08-01)